Omnicell (NASDAQ:OMCL) Posts Earnings Results, Beats Expectations By $0.47 EPS

Omnicell (NASDAQ:OMCL) posted its quarterly earnings data on Thursday. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47, Briefing.com reports. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. During the same period in the previous year, the business earned $0.45 earnings per share. The business’s revenue was up 7.4% compared to the same quarter last year. Omnicell updated its Q3 2026 guidance to 0.350-0.430 EPS and its FY 2026 guidance to 2.150-2.300 EPS.

Here are the key takeaways from Omnicell’s conference call:

• Strong Q2 execution: Revenue reached $312 million, while non-GAAP EBITDA of $67 million and EPS of $0.94 exceeded expectations. Results benefited from a one-time $15 million tariff refund, but underlying EBITDA of $52 million still surpassed prior guidance.
• Bookings visibility weakened: Full-year product bookings guidance was reduced to $425 million–$560 million from a previously higher floor, reflecting uncertainty over the timing of medium- and large-customer decisions and lengthy capital approval cycles. Management said the lower end reflects timing rather than deteriorating demand.
• Titan XT and OmniSphere momentum: Titan XT remains on track to ship in the second half of 2026, with OmniSphere ADS targeted for general availability in the first half of 2027. The company reported its first competitive Titan XT conversion of the year and continued strong pipeline activity among both existing and competitor customers.
• Cost and outlook headwinds remain: Full-year revenue and ARR guidance were moderated, partly because consumables growth opportunities are taking longer to develop. Memory-chip supply constraints are expected to add approximately $6 million in second-half costs and reduce full-year consolidated gross margin by about 50 basis points.
• Profitability outlook increased: Despite the more cautious bookings and revenue timing outlook, Omnicell raised full-year non-GAAP EBITDA guidance to $175 million–$185 million and EPS guidance to $2.15–$2.30, citing operating discipline, improved leverage, and the tariff refund.

Omnicell Price Performance

OMCL stock traded down $1.70 during midday trading on Friday, reaching $35.41. The stock had a trading volume of 707,849 shares, compared to its average volume of 659,239. The company’s fifty day simple moving average is $42.16 and its 200 day simple moving average is $41.13. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.61 billion, a price-to-earnings ratio of 80.28, a price-to-earnings-growth ratio of 1.07 and a beta of 0.96. Omnicell has a 52-week low of $28.90 and a 52-week high of $55.00.

Wall Street Analysts Forecast Growth

OMCL has been the subject of a number of research analyst reports. Wells Fargo & Company reduced their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday. Zacks Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. KeyCorp decreased their price target on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $58.43.

Insiders Place Their Bets

In other news, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the sale, the executive vice president owned 154,785 shares of the company’s stock, valued at $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at $4,874,481.26. This trade represents a 4.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by corporate insiders.

Institutional Trading of Omnicell

Several large investors have recently bought and sold shares of the business. Vontobel Holding Ltd. purchased a new position in Omnicell in the 4th quarter worth approximately $306,000. Creative Planning boosted its holdings in shares of Omnicell by 16.7% during the 2nd quarter. Creative Planning now owns 9,390 shares of the company’s stock worth $276,000 after purchasing an additional 1,347 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Omnicell in the fourth quarter valued at approximately $274,000. Magnetar Financial LLC purchased a new stake in shares of Omnicell in the third quarter valued at approximately $230,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Omnicell in the third quarter valued at approximately $224,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell News Roundup

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Omnicell reported adjusted EPS of $0.94, versus the $0.47–$0.48 consensus, while revenue rose 7.4% year over year to $312.2 million, slightly ahead of estimates. GAAP net income increased to $24 million from $6 million a year earlier. Omnicell Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Full-year profitability guidance was raised. Omnicell now expects fiscal 2026 adjusted EPS of $2.15 to $2.30, above the approximately $1.81 analyst consensus. Management cited demand for connected devices, growth in technical services and software-as-a-service offerings, cost discipline, and $15 million of tariff refunds. Full-year revenue guidance was set at $1.225 billion to $1.245 billion. Omnicell Q2 Non-GAAP Net Income, Revenue Increase; 2026 Non-GAAP EPS Outlook Lifted
• Positive Sentiment: Product momentum remains a longer-term catalyst. The company highlighted growth opportunities for its Titan XT and OmniSphere platforms and continued pipeline expansion. OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth
• Neutral Sentiment: KeyCorp remains bullish but reduced its price target. The firm cut its target from $70 to $65 while retaining an “overweight” rating, indicating continued confidence but somewhat more cautious valuation expectations.
• Negative Sentiment: Third-quarter guidance disappointed. Omnicell forecast adjusted EPS of $0.35 to $0.43 and revenue of $301 million to $307 million, below consensus estimates of $0.43 EPS and $312.6 million revenue. Management also noted that customer approval timing is delaying some product bookings, which overshadowed the quarterly beat and raised full-year outlook. Omnicell Q2 CY2026 Beats on Revenue but Stock Drops on Weak Guidance

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.